# Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

> **NCT01127750** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 2417 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** FTY720

## Key facts

- **NCT ID:** NCT01127750
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 2417 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127750, "Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01127750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*